{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:12:18Z","timestamp":1793077938753,"version":"4.5.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brain metastases affect a significant percentage of patients with advanced extracranial malignancies. Yet, the incidence of brain metastases remains poorly described, largely due to limitations of population-based registries, a lack of mandated reporting of brain metastases to federal agencies, and historical difficulties with delineation of metastatic involvement of individual organs using claims data. However, in 2016, the Surveillance Epidemiology and End Results (SEER) program released data relating to the presence vs absence of brain metastases at diagnosis of oncologic disease. In 2020, studies demonstrating the viability of utilizing claims data for identifying the presence of brain metastases, date of diagnosis of intracranial involvement, and initial treatment approach for brain metastases were published, facilitating epidemiologic investigations of brain metastases on a population-based level. Accordingly, in this review, we discuss the incidence, clinical presentation, prognosis, and management patterns of patients with brain metastases. Leptomeningeal disease is also discussed. Considerations regarding individual tumor types that commonly metastasize to the brain are provided.<\/jats:p>","DOI":"10.1093\/neuonc\/noab101","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:30:28Z","timestamp":1619109028000},"page":"1447-1456","source":"Crossref","is-referenced-by-count":401,"title":["Epidemiology of brain metastases and leptomeningeal disease"],"prefix":"10.1093","volume":"23","author":[{"given":"Nayan","family":"Lamba","sequence":"first","affiliation":[{"name":"Harvard Radiation Oncology Program, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A","family":"Aizer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"1","key":"2021091306412586600_CIT0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep."},{"issue":"7","key":"2021091306412586600_CIT0002","first-page":"941","article-title":"Management of brain metastases","volume":"13","author":"Wen","year":"1999","journal-title":"Oncology (Williston Park)."},{"issue":"14","key":"2021091306412586600_CIT0003","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"2021091306412586600_CIT0004","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2014.58.4508","article-title":"Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial","volume":"33","author":"Rapp","year":"2015","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021091306412586600_CIT0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"2021091306412586600_CIT0006","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021091306412586600_CIT0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","article-title":"Brain metastases: epidemiology","volume":"149","author":"Ostrom","year":"2018","journal-title":"Handb Clin Neurol."},{"issue":"9","key":"2021091306412586600_CIT0008","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/neuonc\/noaa054","article-title":"Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis","volume":"22","author":"Lamba","year":"2020","journal-title":"Neuro Oncol."},{"issue":"16","key":"2021091306412586600_CIT0009","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon","year":"2007","journal-title":"J Clin Oncol."},{"key":"2021091306412586600_CIT0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.critrevonc.2019.07.012","article-title":"Systemic therapy for brain metastases","volume":"142","author":"Rick","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"issue":"4","key":"2021091306412586600_CIT0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nec.2020.06.001","article-title":"Epidemiology of brain metastases","volume":"31","author":"Sacks","year":"2020","journal-title":"Neurosurg Clin N Am."},{"issue":"11","key":"2021091306412586600_CIT0012","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021091306412586600_CIT0013","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol."},{"key":"2021091306412586600_CIT0014","author":"National Cancer Institute"},{"issue":"3","key":"2021091306412586600_CIT0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-009-9943-z","article-title":"Utility of administrative claims data for the study of brain metastases: a validation study","volume":"95","author":"Eichler","year":"2009","journal-title":"J Neurooncol."},{"issue":"4","key":"2021091306412586600_CIT0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/neuonc\/noz245","article-title":"Utility of claims data for identification of date of diagnosis of brain metastases","volume":"22","author":"Lamba","year":"2020","journal-title":"Neuro Oncol."},{"key":"2021091306412586600_CIT0017","author":"National Comprehensive Cancer Network"},{"key":"2021091306412586600_CIT0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-811161-1.00007-4","article-title":"Brain metastases: neuroimaging","volume":"149","author":"Pope","year":"2018","journal-title":"Handb Clin Neurol."},{"issue":"1","key":"2021091306412586600_CIT0019","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-020-06897-z","article-title":"Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee","volume":"20","author":"Kiesel","year":"2020","journal-title":"BMC Cancer."},{"issue":"6","key":"2021091306412586600_CIT0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM)","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"issue":"21","key":"2021091306412586600_CIT0021","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021091306412586600_CIT0022","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","article-title":"Brain metastases in newly diagnosed breast cancer: a population-based study","volume":"3","author":"Martin","year":"2017","journal-title":"JAMA Oncol."},{"issue":"5","key":"2021091306412586600_CIT0023","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/1055-9965.EPI-18-1116","article-title":"Lifetime occurrence of brain metastases arising from lung, breast, and skin cancers in the elderly: a SEER-Medicare study","volume":"28","author":"Ascha","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"5","key":"2021091306412586600_CIT0024","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"2021091306412586600_CIT0025","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov."},{"key":"2021091306412586600_CIT0026","author":"National Comprehensive Cancer Network"},{"issue":"7","key":"2021091306412586600_CIT0027","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of screening for brain metastases in patients with breast cancer and non-small cell lung cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol."},{"issue":"8","key":"2021091306412586600_CIT0028","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1212\/WNL.0000000000011459","article-title":"Seizures among patients with brain metastases: a population- and institutional-level analysis","volume":"96","author":"Lamba","year":"2021","journal-title":"Neurology"},{"key":"2021091306412586600_CIT0029","first-page":"75","article-title":"Chapter 6 - Brain metastasis: clinical manifestations, symptom management, and palliative care","volume-title":"Handbook of Clinical Neurology","author":"Noh","year":"2018"},{"key":"2021091306412586600_CIT0030","doi-asserted-by":"crossref","first-page":"e1557","DOI":"10.1016\/j.wneu.2018.11.100","article-title":"Neurosurgical resection and stereotactic radiation versus stereotactic radiation alone in patients with a single or solitary brain metastasis","volume":"122","author":"Lamba","year":"2019","journal-title":"World Neurosurg."},{"issue":"4","key":"2021091306412586600_CIT0031","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2021091306412586600_CIT0032","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/neuonc\/noaa233","article-title":"Population-based estimates of survival among elderly patients with brain metastases","volume":"23","author":"Lamba","year":"2020","journal-title":"Neuro Oncol."},{"issue":"32","key":"2021091306412586600_CIT0033","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol."},{"issue":"21","key":"2021091306412586600_CIT0034","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA."},{"issue":"4","key":"2021091306412586600_CIT0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA."},{"issue":"5","key":"2021091306412586600_CIT0036","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ijrobp.2011.10.025","article-title":"Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy","volume":"83","author":"Park","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"17","key":"2021091306412586600_CIT0037","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA."},{"issue":"8","key":"2021091306412586600_CIT0038","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"2021091306412586600_CIT0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2021091306412586600_CIT0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminoncol.2020.07.008","article-title":"Systemic therapy for metastatic HER2-positive breast cancer","volume":"47","author":"Bredin","year":"2020","journal-title":"Semin Oncol."},{"issue":"8","key":"2021091306412586600_CIT0041","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med."},{"issue":"9422","key":"2021091306412586600_CIT0042","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet."},{"issue":"10","key":"2021091306412586600_CIT0043","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/neuonc\/noaa175","article-title":"Utility of claims data for delineation of intracranial treatment among patients with brain metastases","volume":"22","author":"Lamba","year":"2020","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021091306412586600_CIT0044","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol."},{"issue":"17","key":"2021091306412586600_CIT0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA."},{"issue":"2","key":"2021091306412586600_CIT0046","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021091306412586600_CIT0047","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2016.10.005","article-title":"Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: results from a randomized trial","volume":"121","author":"K\u0119pka","year":"2016","journal-title":"Radiother Oncol."},{"issue":"8","key":"2021091306412586600_CIT0048","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"2021091306412586600_CIT0049","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of neurosurgical resection with development of pachymeningeal seeding in patients with brain metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol."},{"issue":"1","key":"2021091306412586600_CIT0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cncr.30911","article-title":"Leptomeningeal metastasis from systemic cancer: review and update on management","volume":"124","author":"Wang","year":"2018","journal-title":"Cancer."},{"issue":"6","key":"2021091306412586600_CIT0051","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021091306412586600_CIT0052","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctro.2019.06.008","article-title":"EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis","volume":"18","author":"Mitra","year":"2019","journal-title":"Clin Transl Radiat Oncol."},{"issue":"4","key":"2021091306412586600_CIT0053","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"2021091306412586600_CIT0054","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase \u00bd study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021091306412586600_CIT0055","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021091306412586600_CIT0056","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"issue":"6","key":"2021091306412586600_CIT0057","doi-asserted-by":"crossref","first-page":"OF4","DOI":"10.1158\/2159-8290.CD-NB2020-038","article-title":"Capmatinib could alter NSCLC treatment landscape","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"2021091306412586600_CIT0058","article-title":"Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases","volume":"3","author":"Guo","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"2021091306412586600_CIT0059","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer."},{"issue":"7781","key":"2021091306412586600_CIT0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature."},{"issue":"18","key":"2021091306412586600_CIT0061","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med."},{"issue":"12","key":"2021091306412586600_CIT0062","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase ii extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021091306412586600_CIT0063","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1002\/cncr.33196","article-title":"Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases","volume":"126","author":"Qian","year":"2020","journal-title":"Cancer."},{"issue":"7","key":"2021091306412586600_CIT0064","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"2021091306412586600_CIT0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"2021091306412586600_CIT0066","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer."},{"issue":"2","key":"2021091306412586600_CIT0067","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol."},{"issue":"5","key":"2021091306412586600_CIT0068","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/1097-0142(197911)44:5<1885::AID-CNCR2820440550>3.0.CO;2-F","article-title":"CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival","volume":"44","author":"Nugent","year":"1979","journal-title":"Cancer."},{"issue":"7","key":"2021091306412586600_CIT0069","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med."},{"issue":"7","key":"2021091306412586600_CIT0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","article-title":"Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC Cohort Study","volume":"6","author":"Rusthoven","year":"2020","journal-title":"JAMA Oncol."},{"key":"2021091306412586600_CIT0071","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1748-717X-9-152","article-title":"Upfront stereotactic radiosurgery in patients with brain metastases from small cell lung cancer: retrospective analysis of 41 patients","volume":"9","author":"Yomo","year":"2014","journal-title":"Radiat Oncol."},{"issue":"8","key":"2021091306412586600_CIT0072","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/cncr.21322","article-title":"Leptomeningeal metastases from small cell lung carcinoma","volume":"104","author":"Seute","year":"2005","journal-title":"Cancer."},{"issue":"11","key":"2021091306412586600_CIT0073","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: an overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Res."},{"key":"2021091306412586600_CIT0074","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.wneu.2020.04.087","article-title":"Severe radiation necrosis refractory to surgical resection in patients with melanoma and brain metastases managed with ipilimumab\/nivolumab and brain-directed stereotactic radiation therapy","volume":"139","author":"Shi","year":"2020","journal-title":"World Neurosurg."},{"issue":"6","key":"2021091306412586600_CIT0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/COC.0b013e3181f9456a","article-title":"Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma","volume":"34","author":"Bedikian","year":"2011","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"2021091306412586600_CIT0076","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3171\/2017.1.JNS162797","article-title":"Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome","volume":"129","author":"Kotecha","year":"2018","journal-title":"J Neurosurg."},{"key":"2021091306412586600_CIT0077","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-13-45","article-title":"MEK targeting in N-RAS mutated metastatic melanoma","volume":"13","author":"Thumar","year":"2014","journal-title":"Mol Cancer."},{"issue":"8","key":"2021091306412586600_CIT0078","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther."},{"issue":"19","key":"2021091306412586600_CIT0079","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med."},{"issue":"8","key":"2021091306412586600_CIT0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081133","article-title":"Atypical BRAF and NRAS mutations in mucosal melanoma","volume":"11","author":"Dumaz","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2021091306412586600_CIT0081","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun."},{"issue":"4","key":"2021091306412586600_CIT0082","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-015-0330-z","article-title":"Treatment of NRAS-mutant melanoma","volume":"16","author":"Johnson","year":"2015","journal-title":"Curr Treat Options Oncol."},{"issue":"2","key":"2021091306412586600_CIT0083","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/jid.2014.417","article-title":"KIT in melanoma: many shades of gray","volume":"135","author":"Slipicevic","year":"2015","journal-title":"J Invest Dermatol."},{"key":"2021091306412586600_CIT0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/OTT.S20257","article-title":"Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents","volume":"4","author":"Khan","year":"2011","journal-title":"Onco Targets Ther."},{"issue":"8","key":"2021091306412586600_CIT0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"9","key":"2021091306412586600_CIT0086","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","article-title":"Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort","volume":"6","author":"Iorgulescu","year":"2018","journal-title":"Cancer Immunol Res."},{"issue":"7","key":"2021091306412586600_CIT0087","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2021091306412586600_CIT0088","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"key":"2021091306412586600_CIT0089","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","author":"Bander","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"2021091306412586600_CIT0090","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer."},{"issue":"12","key":"2021091306412586600_CIT0091","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdq239","article-title":"Incidence of and survival following brain metastases among women with inflammatory breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol."},{"issue":"8","key":"2021091306412586600_CIT0092","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","article-title":"Subtype switching in breast cancer brain metastases: a multicenter analysis","volume":"22","author":"Hulsbergen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"9","key":"2021091306412586600_CIT0093","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro Oncol."},{"issue":"23","key":"2021091306412586600_CIT0094","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021091306412586600_CIT0095","article-title":"Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib","volume":"4","author":"Batalini","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"2021091306412586600_CIT0096","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2021091306412586600_CIT0097","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/tbj.13433","article-title":"Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes","volume":"25","author":"Znidaric","year":"2019","journal-title":"Breast J."},{"issue":"5","key":"2021091306412586600_CIT0098","first-page":"2057","article-title":"Prolonged survival of patients with breast cancer-related leptomeningeal metastases","volume":"33","author":"Le Rhun","year":"2013","journal-title":"Anticancer Res."},{"issue":"3","key":"2021091306412586600_CIT0099","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3340\/jkns.2012.52.3.193","article-title":"Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases","volume":"52","author":"Jung","year":"2012","journal-title":"J Korean Neurosurg Soc."},{"key":"2021091306412586600_CIT0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2019.01.020","article-title":"Leptomeningeal carcinomatosis in patients with breast cancer","volume":"135","author":"Franzoi","year":"2019","journal-title":"Crit Rev Oncol Hematol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab101\/38270184\/noab101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/9\/1447\/40352585\/noab101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/9\/1447\/40352585\/noab101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T02:42:20Z","timestamp":1631500940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/9\/1447\/6256866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":100,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,4,28]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab101","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,4,28]]}}}